Your browser doesn't support javascript.
loading
Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study.
DE Sanctis, Vitaliana; DI Rocco, Alice; Cox, Maria Christina; Valeriani, Maurizio; Congedi, Francesca Perrone; Anzellini, Dimitri; Massaro, Maria; Vullo, Gianluca; Facondo, Giuseppe; DE Giacomo, Flavia; Alfò, Marco; Prosperi, Daniela; Pizzichini, Patrizia; Pelliccia, Sabrina; Tafuri, Agostino; Martelli, Maurizio; Osti, Mattia Falchetto.
Afiliação
  • DE Sanctis V; Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
  • DI Rocco A; Department of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Rome, Italy.
  • Cox MC; Hematology Institute, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
  • Valeriani M; Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
  • Congedi FP; Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
  • Anzellini D; Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
  • Massaro M; Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
  • Vullo G; Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy gianluca.vullo@uniroma1.it.
  • Facondo G; Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
  • DE Giacomo F; Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
  • Alfò M; Department of Statistical Sciences, Sapienza University of Rome, Rome, Italy.
  • Prosperi D; Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Sapienza University of Rome, Rome, Italy.
  • Pizzichini P; Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Sapienza University of Rome, Rome, Italy.
  • Pelliccia S; Hematology Institute, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
  • Tafuri A; Hematology Institute, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
  • Martelli M; Department of Clinic and Molecular Medicine and Hematology, Sapienza, University of Rome and S. Andrea University Hospital of Rome, Rome, Italy.
  • Osti MF; Department of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Rome, Italy.
In Vivo ; 34(3): 1407-1413, 2020.
Article em En | MEDLINE | ID: mdl-32354938
AIM: To evaluate the efficacy of residual site radiation therapy (RSRT) on local control (LC), progression-free (PFS) and overall (OS) survival in patients with primary mediastinal lymphoma (PMBCL), following rituximab and chemotherapy treatment (ICHT). PATIENTS AND METHODS: The study included 34 patients with PMBCL treated between 2006 and 2014 with ICHT with/without autologous stem cell transplantation and RSRT. Between the end of ICHT/stem cell transplantation and RSRT, patients were evaluated with 18F-fluorodeoxyglucose positron-emission tomography. The gross tumor volume included morphological mediastinal residual disease after ICHT/SCT. The percentage of LC, PFS and OS were assessed. RESULTS: All patients received RSRT with a median dose of 30 Gy. Median follow-up was 82 months. One patient out of 34 (3%) showed progressive disease 9 months from diagnosis. The 10-year PFS and OS were 97% and 97% respectively. CONCLUSION: RSRT in patients with PMBCL treated with ICHT did not impact unfavorably on LC and patient survival.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Neoplasia Residual / Neoplasias do Mediastino Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Neoplasia Residual / Neoplasias do Mediastino Idioma: En Ano de publicação: 2020 Tipo de documento: Article